In a recent clinical study of nivolumab plus chemotherapy in patients with advanced unresectable or metastatic gastric, GEJ, or esophageal adenocarcinoma with no known HER2-positivity (CheckMate 649, NCT02872116), 60% of randomly assigned patients had tumors with a PD-L1 CPS ≥ 5 [9]. This evidence concerns the gene ERBB2 and esophageal adenocarcinoma.